Detective work: reading fine print, insurers question studies of drugs; Kaiser's veteran sleuth scours medical-journal articles and sees marketing spin; doctors fear loss of choices.
Mathews
Anna Wilde
AW
D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use; D035843:Biomedical Research / Q000592:standards*; D002140:California; D002986:Clinical Trials as Topic / Q000592:standards; D003363:Cost Control; D003511:Cyclohexanols; D008192:Deception; D016527:Drug Costs; D004345:Drug Industry; D000068736:Duloxetine Hydrochloride; D005569:Formularies as Topic; D006279:Health Maintenance Organizations; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D008389:Marketing of Health Services; D011643:Publishing; D012107:Research Design / Q000592:standards*; D013876:Thiophenes; D014481:United States; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride; D000068736:Duloxetine Hydrochloride